Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?

@article{Montravers2006CanFP,
  title={Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?},
  author={Françoise Montravers and Dany Grahek and Khaldoun Kerrou and Ph. Ruszniewski and Virginie de Beco and Nicolas Aide and Fabrice Gutman and J{\'e}r{\^o}me Grange and Jean-pierre Lotz and Jean-no{\"e}l Talbot},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2006},
  volume={47 9},
  pages={
          1455-62
        }
}
UNLABELLED The aim of this study was to evaluate whether (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET is accurate for the diagnosis and follow-up of any type of well-differentiated digestive endocrine tumor and to assess its performance compared with standard somatostatin receptor scintigraphy (SRS) using (111)In-pentetreotide. METHODS We reviewed the results of 33 evaluable (18)F-FDOPA PET and (111)In-pentetreotide SRS examinations performed between March 2002 and September 2005 in… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

Similar Papers

Loading similar papers…